Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial

Table 3 NAPSI and PASI of patients continuing vs withdrawing guselkumab, by prior biologic use

Variable, mean (S.D)	Week 0	Week 16	Week 24	Week 48
**Guselkumab response continuation; bio-naïve patients**
Treatment received	Guselkumab			Re-randomized to guselkumab at week 28
NAPSI	4.5 (1.9)	2.5 (2.2)	1.8 (2.0)	1.2 (1.7)
n	85	83	84	82
PASI	22.1 (8.4)	1.2 (2.2)	0.6 (1.0)	1.0 (1.8)
n	85	85	85	83
**Guselkumab response continuation; bio-experienced patients**
Treatment received	Guselkumab			Re-randomized to guselkumab at week 28
NAPSI	4.1 (1.6)	2.0 (2.1)	1.7 (2.1)	0.9 (1.3)
n	23	23	23	23
PASI	24.3 (10.0)	1.2 (1.7)	0.8 (1.5)	2.5 (6.6)
n	23	23	23	23
**Guselkumab response withdrawal; bio-naïve patients**
Treatment received	Guselkumab			Re-randomized to placebo at week 28
NAPSI	4.8 (2.0)	2.5 (2.0)	1.6 (1.9)	1.8 (2.2)
n	81	80	80	80
PASI	22.8 (9.2)	1.2 (2.4)	0.5 (1.4)	5.0 (6.1)
n	85	85	84	84
**Guselkumab response withdrawal; bio-experienced patients**
Treatment received	Guselkumab			Re-randomized to placebo at week 28
NAPSI	5.9 (1.8)	2.3 (1.4)	2.3 (2.0)	2.3 (1.7)
n	16	16	16	16
PASI	24.4 (8.3)	2.0 (3.6)	0.9 (0.8)	6.4 (6.0)
n	16	16	16	16

Response is defined as achievement of PASI90 response (≥ 90% improvement in PASI score from baseline) at week 28
NAPSI Nail Psoriasis Severity Index, PASI Psoriasis Area and Severity Index, S.D Standard deviation

ISSN: 1478-6362